Cell Bio-Systems Launches Beta Production of Patented Injector.Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--June 15, 2004 Cell Bio-Systems, Inc. (Pink Sheets:CBSI CBSI CUNA Brokerage Services, Inc. CBSI Cambodian Buddhist Society, Inc. (Silver Springs, Maryland) CBSI Certified Bridge Safety Inspector CBSI Custom Business Solutions, Inc. ), a biotechnology company seeking to manufacture and distribute patented, disposable technologies for cosmetic surgery cosmetic surgery, plastic surgery for cosmetic purposes, such as the improvement of the appearance of the face by removing wrinkles or reshaping the nose. and other living tissue procedures, announced today that it will begin limited production of the company's flagship instrument, the Super-Luer injector, next week. The production run will provide samples for preliminary evaluations - such as coefficient friction testing, validation testing for coating applications, and strength testing strength testing, n assessment procedure to determine the contractile strength of a muscle. , prior to the distribution of test kits for surgeon evaluations. These early products also will allow Cell Bio-Systems to establish manufacturing protocols and complete a pending 510K notification to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in support of the company's claims. The products produced will utilize the company's already approved tip styles. "This is a very important milestone in the process of bringing a medical device to market," said Marc Pilkington, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cell Bio-Systems. "Though we have successfully completed testing on prototypes, scientific validation of our claims with the actual production products will be a significant step in backing up what we have known all along about the superiority of these new devices." The Super-Luer is a patented connection system that will serve as the centerpiece component for the company's bio-device kits utilized in procedures ranging from liposuction Liposuction Definition Liposuction, also known as lipoplasty or suction-assisted lipectomy, is cosmetic surgery performed to remove unwanted deposits of fat from under the skin. and fat re-injections to gene therapy technologies and stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research. It will be adapted to manufacture the first affordable, disposable cannula cannula /can·nu·la/ (kan´u-lah) a tube for insertion into a vessel, duct, or cavity; during insertion its lumen is usually occupied by a trocar. can·nu·la or can·u·la n. pl. in the marketplace. A cannula is an enclosed tubular device, currently made from stainless steel stainless steel: see steel. stainless steel Any of a family of alloy steels usually containing 10–30% chromium. The presence of chromium, together with low carbon content, gives remarkable resistance to corrosion and heat. , that looks much like a large needle and has been popularized by its use to insert or extract tissue during liposuction and collagen implant procedures. Though re-sterilized, steel cannulas are reused in hundreds of procedures, typically for as long as two years or more. Despite safety concerns and complications regularly ascribed to steel cannulas, no comparable, disposable device currently exists. About Cell Bio-Systems Based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(TM) procedures. The company is developing an affordable, disposable product line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. CBSI shareholders are encouraged to visit http://www.cellbiosystems.com and to register on the "Investor Relations" page to receive ongoing CBSI news updates. Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion